Inhibition of cell death and induction of G2 arrest accumulation in human ovarian clear cells by HNF-1β transcription factor chemosensitivity is regulated by checkpoint kinase chk1

International Journal of Gynecological Cancer

Volumn 24, Issue 5, 2014, Pages 838-843

  Shigetomi, Hiroshi ^a   Sudo, Tamotsu ^b   Shimada, Keiji ^a   Uekuri, Chiharu ^a   Tsuji, Yoriko ^a   Kanayama, Seiji ^a   Naruse, Katsuhiko ^a   Yamada, Yoshihiko ^c   Konishi, Noboru ^a   Kobayashi, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b HYOGO CANCER CENTER   (Japan)

^c Yao Municipal Hospital   (Japan)

Author keywords

Cell cycle; Checkpoint control; Chemoresistance; DNA damage response; Transcription factors

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHECKPOINT KINASE 1; HEPATOCYTE NUCLEAR FACTOR 1BETA; HNF1B PROTEIN, HUMAN; PROTEIN KINASE; SMALL INTERFERING RNA;

ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; OVARY ADENOCARCINOMA; OVARY CELL; OVARY CLEAR CELL ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG RESISTANCE; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA, CLEAR CELL; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; G2 PHASE; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; OVARIAN NEOPLASMS; PROTEIN KINASES; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84904099472     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000136     Document Type: Article

References (21)

1. Melin A, Sparén P, Bergqvist A. The risk of cancer and the role of parity among women with endometriosis. Hum Reprod. 2007;22:3021-3026.
2. Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol. 2001;127:73-79.
3. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005;18:S19-S32.
4. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am. 1997;24:235-258.
5. Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. 5th ed. New York, NY: Springer-Verlag. 2002;791-904.
6. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584-2589.
7. Ikeda K, Sakai K, Yamamoto R, et al. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer. 2003;13:776-784.
8. Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003.
9. Kaku T, Ogawa S, Kawano Y, et al. Histological classification of ovarian cancer. Med Electron Microsc. 2003;36:9-17.
10. Gynecologic Cancer Committee, Japan Society of Obstetrics and Gynecology. Annual report of gynecological cancer patients in Japan 2006 [in Japanese]. Acta Obstet Gynaecol Jpn. 2008;60:1001-1085.
11. Yamaguchi K, Mandai M, Toyokuni S, et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res. 2008;14:32-40.
12. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003;163:2503-2512.
13. Kobayashi H, Yamada Y, Kanayama S, et al. The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2009;19:471-479.
14. Yoshida S, Furukawa N, Haruta S, et al. Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives. Cancer Treat Rev. 2009;35:608-615.
15. Kobayashi H, Kajiwara H, Kanayama S, et al. Molecular pathogenesis of endometriosis-Associated clear cell carcinoma of the ovary (review). Oncol Rep. 2009;22:233-240.
16. O'Connor PM, Fan S. DNA damage checkpoints: implications for cancer therapy. Prog Cell Cycle Res. 1996;2:165-173.
17. Itamochi H, Kigawa J, Akeshima R, et al. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology. 2002;62:349-353.
18. Zhang YW, Brognard J, Coughlin C, et al. The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol Cell. 2009;35:442-453.
19. Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol. 2005;5:366-373.
20. Zabludoff SD, Deng C, Grondine MR, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 2008;7:2955-2966.
21. Ganzinelli M, Carrassa L, Crippa F, et al. Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clin Cancer Res. 2008;14:5131-5141.